Skip to main content

Vertex Pharmaceuticals Value Stock - Dividend - Research Selection


ISIN: US92532F1003 , WKN: 882807

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever

These stocks probably won't be getting much cheaper.

THQ: Collecting A High Yield From Increased Medical Spending

abrdn Healthcare Opportunities Fund (THQ) offers a high dividend yield and exposure to diverse healthcare subsectors, outperforming peers. Explore more here.

3 Relatively Safe Growth Stocks You Can Buy and Hold

Low risk and high-reward potential? These stocks could offer both.

3 Biotech Stocks Set to Double by 2028

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $394.28, indicating a +0.2% shift from the previous trading day.

Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug

Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.

Vertex Announces Advancements of Suzetrigine in Acute and Neuropathic Pain

BOSTON - Vertex Pharmaceuticals Incorporated today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and...

Is Vertex Pharmaceuticals Stock a Millionaire Maker?

Does this pharma stock have the potential to turn a $25,000 investment into seven figures or more?

CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?

The biotech just added another potential growth driver to its pipeline.